Spastic paraplegia type 11

Spastic paraplegia type 11 is part of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterized by progressive muscle stiffness (spasticity) and the development of paralysis of the lower limbs (paraplegia). Hereditary spastic paraplegias are divided into two types: pure and complex. The pure types involve the lower limbs. The complex types involve the lower limbs and can affect the upper limbs to a lesser degree. Complex spastic paraplegias also affect the structure or functioning of the brain and the peripheral nervous system, which consists of nerves connecting the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound. Spastic paraplegia type 11 is a complex hereditary spastic paraplegia.

Like all hereditary spastic paraplegias, spastic paraplegia type 11 involves spasticity of the leg muscles and muscle weakness. In almost all individuals with this type of spastic paraplegia, the tissue connecting the left and right halves of the brain (corpus callosum) is abnormally thin. People with this form of spastic paraplegia can also experience numbness, tingling, or pain in the arms and legs (sensory neuropathy); disturbance in the nerves used for muscle movement (motor neuropathy); intellectual disability; exaggerated reflexes (hyperreflexia) of the lower limbs; speech difficulties (dysarthria); reduced bladder control; and muscle wasting (amyotrophy). Less common features include difficulty swallowing (dysphagia), high-arched feet (pes cavus), an abnormal curvature of the spine (scoliosis), and involuntary movements of the eyes (nystagmus). The onset of symptoms varies greatly; however, abnormalities in muscle tone and difficulty walking usually become noticeable in adolescence.

Many features of spastic paraplegia type 11 are progressive. Most people experience a decline in intellectual ability and an increase in muscle weakness and nerve abnormalities over time. As the condition progresses, some people require wheelchair assistance.

Frequency

Over 100 cases of spastic paraplegia type 11 have been reported. Although this condition is thought to be rare, its exact prevalence is unknown.

Causes

Mutations in the \( SPG11 \) gene cause spastic paraplegia type 11. The \( SPG11 \) gene provides instructions for making the protein spatacsin. Spatacsin is active (expressed) throughout the nervous system, although its exact function is unknown. Researchers speculate that spatacsin may be involved in the maintenance of axons, which are
specialized extensions of nerve cells (neurons) that transmit impulses throughout the nervous system.

SPG11 gene mutations typically change the structure of the spatacsin protein. The effect that the altered spatacsin protein has on the nervous system is not known. Researchers suggest that mutations in spatacsin may cause the signs and symptoms of spastic paraplegia type 11 by interfering with the protein's proposed role in the maintenance of axons.

Inheritance Pattern

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- autosomal recessive spastic paraplegia complicated with thin corpus callosum
- autosomal recessive spastic paraplegia with mental impairment and thin corpus callosum
- HSP-TCC
- SPG11-related hereditary spastic paraplegia with thin corpus callosum

Diagnosis & Management

Genetic Testing Information

- What is genetic testing? /primer/testing/genetictesting
- Genetic Testing Registry: Spastic paraplegia 11, autosomal recessive

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22spastic+paraplegia+type+11%22+OR+%22Spastic+Paraplegia%22+OR+%22Spastic+Paraplegia%22

Other Diagnosis and Management Resources

- GeneReview: Spastic Paraplegia 11
  https://www.ncbi.nlm.nih.gov/books/NBK1210
- Spastic Paraplegia Foundation, Inc.: Treatments and Therapies
  https://sp-foundation.org/understanding-pls-hsp/treatments.html
Additional Information & Resources

**Health Information from MedlinePlus**
- Health Topic: Neuromuscular Disorders
  https://medlineplus.gov/neuromusculardisorders.html
- Health Topic: Paralysis
  https://medlineplus.gov/paralysis.html
- Health Topic: Peripheral Nerve Disorders
  https://medlineplus.gov/peripheralnervedisorders.html

**Genetic and Rare Diseases Information Center**
- Spastic paraplegia 11

**Additional NIH Resources**
- National Institute of Neurological Disorders and Stroke: Hereditary Spastic Paraplegia
  https://www.ninds.nih.gov/Disorders/All-Disorders/Hereditary-spastic-paraplegia-Information-Page

**Educational Resources**
- MalaCards: spastic paraplegia 11
  https://www.malacards.org/card/spastic_paraplegia_11
- Merck Manual Home Edition for Patients and Caregivers
- Orphanet: Hereditary spastic paraplegia
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=685
- University of Kansas Medical Center Resource List
  http://www.kumc.edu/gec/support/hsp.html
- Washington University, St. Louis: Neuromuscular Disease Center
  https://neuromuscular.wustl.edu/spinal/fsp.html#spgmu

**Patient Support and Advocacy Resources**
- National Ataxia Foundation
  https://ataxia.org/
- National Organization for Rare Disorders (NORD): Hereditary Spastic Paraplegia
  https://rarediseases.org/rare-diseases/hereditary-spastic-paraplegia/
- RareConnect
  https://www.rareconnect.org/en/community/hereditary-spastic-paraplegia
Clinical Information from GeneReviews

- Spastic Paraplegia 11
  https://www.ncbi.nlm.nih.gov/books/NBK1210

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28SPG11%5BTIAB%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22+AND+%22last+3600+days%22

Catalog of Genes and Diseases from OMIM

- SPASTIC PARAPLEgia 11, AUTOSOMAL RECESSIVE
  http://omim.org/entry/604360

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19105190

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18067136

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18337587
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730021/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18717728


Reviewed: April 2009
Published: December 10, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services